Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:MRTXNASDAQ:RVMDNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.37-0.3%$7.40$5.90▼$34.11$537.94M2.191.43 million shs1.28 million shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARVMDRevolution Medicines$39.77-2.0%$39.02$29.17▼$62.40$7.41B1.11.54 million shs1.61 million shsRXRXRecursion Pharmaceuticals$5.00+1.6%$4.91$3.79▼$12.36$2.03B0.8415.09 million shs26.97 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-1.86%+13.87%-15.06%-71.21%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RVMDRevolution Medicines0.00%-1.22%+2.66%+3.73%+5.10%RXRXRecursion Pharmaceuticals0.00%-10.38%+7.89%-28.07%-46.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.9151 of 5 stars4.34.00.00.02.22.51.3MRTXMirati TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARVMDRevolution Medicines4.4303 of 5 stars4.51.00.04.73.22.50.0RXRXRecursion Pharmaceuticals1.9379 of 5 stars3.21.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29175.30% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/ARVMDRevolution Medicines 3.00Buy$67.0868.68% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.0040.00% UpsideCurrent Analyst Ratings BreakdownLatest MRTX, RXRX, ARVN, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.26N/AN/A$8.17 per share0.90MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39RVMDRevolution Medicines$742K9,983.66N/AN/A$11.09 per share3.59RXRXRecursion Pharmaceuticals$59.82M33.98N/AN/A$1.98 per share2.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ARVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%8/6/2025 (Estimated)Latest MRTX, RXRX, ARVN, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64MRTXMirati TherapeuticsN/A7.547.40RVMDRevolution MedicinesN/A14.2414.24RXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%MRTXMirati TherapeuticsN/ARVMDRevolution Medicines94.34%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%MRTXMirati Therapeutics3.26%RVMDRevolution Medicines8.20%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableRXRXRecursion Pharmaceuticals400406.50 million329.18 millionOptionableMRTX, RXRX, ARVN, and RVMD HeadlinesRecent News About These CompaniesMorgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00June 16 at 12:03 PM | marketbeat.comIs This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?June 16 at 6:03 AM | fool.comLeerink Partnrs Issues Positive Estimate for RXRX EarningsJune 15 at 1:45 AM | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's WhyJune 13 at 2:22 PM | marketbeat.comLeerink Partnrs Has Positive Estimate for RXRX Q2 EarningsJune 13 at 5:50 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?June 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?June 11, 2025 | marketbeat.comInsmed surges on lung drug data; Recursion cuts staffJune 11, 2025 | biopharmadive.comAI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why June 11, 2025 | talkmarkets.comRecursion to lay off 20% of workforce amid biotech funding woesJune 11, 2025 | msn.comRecursion: Lack Of Near-Term Catalysts Leaves The Stock VulnerableJune 11, 2025 | seekingalpha.comRecursion lays off 20% of staff in wake of pipeline cutbacksJune 10, 2025 | fiercebiotech.comRecursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?June 10, 2025 | benzinga.comRecursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts RiskyJune 10, 2025 | seekingalpha.comRecursion Pharma to reduce workforce by 20%June 10, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AIJune 10, 2025 | msn.comWhy Recursion Pharmaceuticals Was Bouncing Higher on TuesdayJune 10, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.9% Higher - Should You Buy?June 10, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Here's What HappenedJune 10, 2025 | marketbeat.comRecursion to lay off 20% of workforce, narrows focus amid biotech downturnJune 10, 2025 | reuters.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Should You Buy?June 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRTX, RXRX, ARVN, and RVMD Company DescriptionsArvinas NASDAQ:ARVN$7.37 -0.02 (-0.27%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.43 (+5.83%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Revolution Medicines NASDAQ:RVMD$39.77 -0.82 (-2.02%) Closing price 04:00 PM EasternExtended Trading$40.14 +0.37 (+0.93%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Recursion Pharmaceuticals NASDAQ:RXRX$5.00 +0.08 (+1.63%) Closing price 04:00 PM EasternExtended Trading$4.93 -0.07 (-1.40%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
